Background
V520 is Merck’s investigational HIV-1 gag Vaccine in an adenovirus serotype 5 vector.

Study Objective
To evaluate the safety, tolerability, and immunogenicity of this vaccine in HIV+ individuals with T-Cells > 500 and Viral load < 50.

Study Design
This is a phase I, randomized, double-blind research study of V520 vs. placebo in patients on a stable HAART regimen. All patients will receive 3 injections (V520 vs. placebo, 3:1) over 6 months with 18 month follow-up. All study drug and laboratory tests will be provided at no charge. Patients will be reimbursed $50/visit up to $1000 for study completion

Major Inclusion Criteria
1) HIV + on stable HAART regimen with viral load < 50 copies/ml.
2) T-Cells > 550

For more information please contact Quest Clinical Research at (415) 353-0800